N/A
N=30
Post Excision/Mohs Scar Laser Resurfacing
Skin Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02130297 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: MMSS for Scar Halves Treated — 8.4; 8.7 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Laser Treatment (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Primary completion
- Mar 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MMSS for Scar Halves Treated |
8.4; 8.7 | — |
| SECONDARY Quantitative Scar Analysis as Measured by Fractal Dimension (Fd) and Lacunarity |
1.778; 1.781; 0.368; 0.345 | — |
| SECONDARY Quartile Scale |
— | — |
Summary
The purpose of this study is to evaluate the potential benefits of treating a surgical scar post excision with an ablative fractionated CO2 laser with the goal of decreasing the appearance and size of the scar.
Eligibility Criteria
Inclusion Criteria
- Must understand and voluntarily sign an informed consent form.
- Must be male or female and aged >18 years at the time of consent.
- Must be able to adhere to the study visit schedule and other protocol requirements.
- Patients undergoing skin excisions of the face/trunk/extremities.
Exclusion Criteria
- Inability to provide voluntary informed consent
- Use of laser or light based treatments to affected areas in past year
- Fitzpatrick Skin types 3-5
- Surgical lesions located on the central chest
- History of keloid formation
- History of Accutane in the last six months
Data sourced from ClinicalTrials.gov (NCT02130297). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.